



## Early View

Research letter

# ***Streptococcus pneumoniae* re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021**

Juliane Ankert, Stefan Hagel, Claudia Schwarz, Kaijie Pan, Liz Wang, Christof von Eiff, Bradford D. Gessner, Christian Theilacker, Mathias W. Pletz

Please cite this article as: Ankert J, Hagel S, Schwarz C, *et al.* *Streptococcus pneumoniae* re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021. *ERJ Open Res* 2023; in press (<https://doi.org/10.1183/23120541.00703-2022>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2023. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

***Streptococcus pneumoniae* re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021**

**Authors:** Juliane Ankert,<sup>1</sup> Stefan Hagel,<sup>1</sup> Claudia Schwarz,<sup>2</sup> Kaijie Pan,<sup>2</sup> Liz Wang,<sup>2</sup> Christof von Eiff,<sup>3</sup> Bradford D. Gessner,<sup>2</sup> Christian Theilacker,<sup>2\*</sup> Mathias W. Pletz<sup>1\*</sup>

\* shared senior authorship

**Affiliations:**

<sup>1</sup> Institute for Infectious Diseases and Infection Control, Jena University Hospital – Friedrich Schiller University Jena, Jena, Germany

<sup>2</sup> Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer, Collegeville, PA, USA

<sup>3</sup> Pfizer Pharma GmbH, Berlin, Germany

**Corresponding author:**

Mathias Pletz, M.D.  
Institute for Infectious Diseases and Infection Control  
Jena University Hospital  
Friedrich Schiller University Jena  
Am Klinikum 1  
07747 Jena/Germany

**Key words:** Community-acquired pneumonia, CAP, pneumococcal conjugate vaccine, pneumococcal vaccination, *Streptococcus pneumoniae*, etiology, Germany

**Funding:** The study was funded by Pfizer Inc.

*To the Editor:*

Following the emergence of the COVID-19 pandemic in early 2020, many countries implemented containment measures to curb the spread of SARS-CoV-2. These containment measures were associated with a substantial reduction in the activity of other respiratory viruses as well as bacterial disease such as pneumococci [1, 2]. Consequently, as containment measures were gradually withdrawn, a rebound of RSV disease in children [3] and increases in pneumococcal diseases (IPD) were observed [4]. However, little is known how increasing population-immunity against SARS-CoV-2, the circulation of new SARS-CoV-2 variants, and withdrawal of containment measures have impacted the microbiology of community-acquired pneumonia (CAP) over time. Here, we describe the etiology of hospitalized CAP among adults in Germany during 2021, the second year of the COVID-19 pandemic. In 2021, Germany had implemented strict COVID-19 containment measures, which were gradually withdrawn over the year and re-implemented before 2022 [5].

This ongoing prospective, population-based surveillance study is conducted since January 4, 2021, at one community and two large tertiary care hospitals in Thuringia, Germany, serving a population of about 280,000 inhabitants. Adult patients with suspicion of lower respiratory tract infection admitted to study hospitals were screened for eligibility and individuals with documented or clinically suspected pneumonia were enrolled. Patients included in this analysis (1) were enrolled between January 1 and December 31 of 2021, (2) had radiologically-confirmed CAP diagnosed within 48 hours of hospital admission, and (3) had information on hospital discharge disposition available. Study staff collected data on patient characteristics, medical history, hospital course, and standard of care microbiologic testing. NPS were tested by PCR for 10 respiratory viruses (SARS-CoV-2, respiratory syncytial virus, influenza virus, parainfluenza virus, human metapneumovirus, rhinovirus, human endemic coronavirus, adenovirus, enterovirus, bocavirus). Urine samples were tested with the pneumococcal urinary antigen test (PUAT, BinaxNOW *S. pneumoniae*) and with proprietary serotype-specific urinary antigen detection (UAD) assays [6, 7]. UAD assays detect all serotypes included in currently licensed vaccines. All data were descriptively summarized. The association of *S. pneumoniae* coinfection among COVID-19 patients with severe outcome adjusted for patient age was analyzed using the Mantel-Haenszel method.

Of 2084 patients with study-qualifying pneumonia, 804 were enrolled, and 760 were included in this analysis (**Figure 1A**). The median age of patients with radiologically-confirmed CAP was 67 years (Q1, Q3: 58, 79) and 57.6% were male. Approximately three quarters (75.9%) of patients had at least one comorbidity. The uptake for same season influenza vaccine, cumulative uptake of 23-valent pneumococcal

polysaccharide vaccine (PPV23), and the 13-valent pneumococcal conjugate vaccine (PCV13) were 23.4%, 25.0% and 3.0%, respectively. The uptake for  $\geq 1$  dose of a COVID-19 vaccine was 14.3% in the first half of 2021 and increased to 50.6% in the second half. The median hospital length of stay was 8 days, 122 patients (16.1%) were admitted to the ICU, 43.7% had a pneumonia severity index (PSI) grade of IV or V, and in-hospital case-fatality rate was 8.4%.

Adherence to the diagnostic testing protocol was high throughout the study period and did not differ between the first and second half of 2021. Overall, 96% of all CAP cases were tested for SARS-CoV-2, 91% for other respiratory viruses, and 80% for *S. pneumoniae* using UAD and PUAT. Additionally, the proportion of CAP cases with prior antibiotic treatment did not differ between the first and second half of 2021 (7.8% and 8.0%, respectively). A respiratory pathogen was detected in 553 (72.8%) patients with CAP. The most frequent pathogen was SARS-CoV-2 (n=498, 68.2%), followed by *S. pneumoniae* (n=40, 6.4%), rhinovirus and parainfluenza virus (n=16, 2.3% each), and RSV (n=14, 2.0%) (**Figure 1D**). Other viruses were infrequent ( $\leq 1.0\%$  each), and no case of influenza was identified. Of the 40 pneumococcal CAP cases, 30 had a positive UAD test, in 17 PUAT was positive, and in 8 *S. pneumoniae* grew from culture (blood, n=6; sputum and tracheal aspirate, n=1 each). The percentage of CAP patients with SARS-CoV-2 detection was higher in patients aged 18 to 59 years (n=176, 79.3%) than those aged  $\geq 60$  years (n=322, 63.4%). Conversely, *S. pneumoniae* was more frequently detected in patients aged  $\geq 60$  years (n=33, 7.8%) than in patients aged 18 to 59 years (n=7, 3.6%). Of the 40 pneumococcal CAP cases, PCV13-, PCV15-, PCV20- and PPV23-included serotypes, accounted for 42.5% (n=17), 45.0% (n=18), 70.0% (n=28), and 73% (n=29). The most frequent serotypes were 3 (n=5), 8 (n=4), and 19A/6A/11A (3 detections each).

The etiology of CAP changed substantially throughout 2021 (**Figure 1**). The monthly proportion of CAP cases associated with SARS-CoV-2 ranged from 76.7% to 93.7% between January and May, dipped to 7.1% in July, and then rose continuously to 82.4% until December (**Figure 1B**). *S. pneumoniae* caused 0.0% to 2.9% of CAP between January and May and accounted for 5.9% to 16.7% afterwards (**Figure 1B**). The proportion of CAP cases associated with SARS-CoV-2 decreased from the first to second half of 2021 in both older adults (from 74.7% to 51.4%) and younger adults (from 88.0% to 72.1%) (**Figure 1C**). By contrast, the proportion of CAP cases associated with *S. pneumoniae* increased between the first and second half of 2021 in older adults from 2.5% to 12.4% and in younger adults from 1.1% to 5.6% (**Figure 1C**).

Similar to *S. pneumoniae*, between the first and second half of 2021, respiratory viruses other than SARS-CoV-2 increased between the first and second half of 2021 from 5.3% to 11.3%. Coinfection of SARS-CoV-2 and *S. pneumoniae* occurred in 2/283 (0.7%) of patients in the first half of 2021, but in 13/215 (6.0%) in

adults  $\geq 18$  years and to 11/127 cases (8.7%) in adults  $\geq 60$  years in the second half of 2021 (**Figure 1C**). Thirteen out of a total of 34 (38.5%) pneumococcal detections in the second half of 2021 were in patients with COVID-19 (**Figure 1C**). We did not find evidence for an association of *S. pneumoniae* coinfection in COVID-19 patients with death after pneumonia (age-adjusted odds ratio [aOR] 1.22, 95% confidence interval [CI] 0.26, 5.72,  $p=0.802$ ), admission to ICU (aOR 1.13, 95% CI 0.31, 4.15,  $p=0.854$ ), or need for mechanical ventilation (aOR 1.55, 95% CI 0.33, 7.24,  $p=0.575$ ). However, due to the relatively low numbers of cases, our analysis was not powered to exclude such an association. Coinfections of SARS-CoV-2 with other respiratory viruses remained unchanged at around 5% over the year 2021.

In this pneumonia surveillance study, we describe changes with CAP etiology in Germany during 2021, covering the time of the spread of the COVID-19 Wuhan strain, and the subsequent waves of Alpha and Delta variants [8]. SARS-CoV-2 was the predominant cause of CAP in 2021, and the percentage of CAP due to *S. pneumoniae* rose from very low levels in early 2021 to near pre-pandemic levels among older patients in the second half of 2021 [9], with 12.4% of CAP cases caused by *S. pneumoniae* and 78.5% of these due to PCV20 serotypes. Previous studies reported that *S. pneumoniae* coinfection was rare among COVID-19 patients but if present, associated with high case-fatality [10, 11]. In the second half of 2021, *S. pneumoniae* was detected in 8.7% of older adults with COVID-19, a coinfection rate higher than recently reported for influenza [12]. The re-emergence of *S. pneumoniae* may be related to several factors, including changes in social mixing with relaxation of containment measures and healthcare seeking behavior, and differences in the interference of individual SARS-CoV-2 variants with other respiratory pathogens [13]. Underestimation of pneumococcal CAP by previous studies may also be related to the low sensitivity of the standard-of-care culture methods compared to urinary antigen testing used in this study.

The main strength of this study lies in the high testing rates of 80% to 96% for 11 respiratory pathogens. A limitation of the study is that only 39% of eligible patients were enrolled. The most common reason for non-enrollment was a lack of capacity to provide consent, possibly reducing the generalizability of our results to severely ill, debilitated patients. However, the proportion of patients with severe disease as measured by PSI grade IV or V in our cohort is similar to that reported in other recent CAP surveillance studies [14, 15]. Also, the roll-out of the COVID-19 vaccination campaign in 2021 preferentially targeted older adults and this may bias comparisons across age groups.

*S. pneumoniae*, the leading bacterial cause of CAP prior to the COVID-19 pandemic, was reduced during the early months of 2021 but rebounded to near pre-pandemic levels after the summer of 2021, affecting both COVID-19 and non-COVID-19 CAP patients in Germany. This rebound occurred in the absence of

influenza circulation. With a more diverse spectrum of CAP etiologies emerging, it will be critical to strengthen vaccination uptake not only for SARS-CoV2, but also for the currently re-emerging influenza [16] and *S. pneumoniae* [17]. Finally, studies with larger sample size should re-evaluate impact of dual infection of SARS-CoV-2 and *S. pneumoniae* on severe clinical outcomes. This study shows that clinicians should be aware that coinfection with SARS-CoV-2 and pneumococci - especially in patients over 60 years of age - is not uncommon and may continue to increase.

**Declarations:** C.T., K.P., L.W., C.S., C.v.E. and B.D.G. are full time employees of Pfizer Vaccines and hold stock and/or stock options. M.W.P. reports research support to his institution from BioNTech, MSD, Roche, Pfizer, Bayer, GSK, Thermo Fisher, AstraZeneca and Novartis, personal fees from MSD, Roche, Pfizer, Bayer, GSK, Thermo Fisher, AstraZeneca and Novartis, support for attending meetings and/or travel from Pfizer and MSD, patents planned, issued or pending from Biological Glass, CO-releasing woven, participation on a Data Safety Monitoring Board or Advisory Board with Inflarx with payment to his institution, and board of directors in CAPNETZ, Paul Ehrlich Society, and WHO Guidance Group COVID-19 with no payments. S.H. reports payments or honoraria from Pfizer, MSD, Infectopharm, Philips, Advanz, Beckman Coulter, Shionogi, Tillots, and Thermo Fisher and support for attending meetings and/or travel from Pfizer, MSD, Infectopharm, Philips, Advanz, Beckman Coulter, Thermo Fisher, Shionogi, and Tillots, and participation on a Data Safety Monitoring Board or Advisory Board with Advanz and Shionogi. J.A. has no declarations.

**Acknowledgements:**

We would like to thank the research team at the University Medical Center Jena, including Sebastian Weis, Christina Bahrs, Anne Moeser, Bettina Löffler, and Steffi Kolanos, the research team at the SRH Klinik Gera, including Dagmar Täuscher, Nancy Schmidt, Nicole Haupt, Sabine Sell, Anne Meinzenbach, Melissa Rohde, Romy Anger, Mandy Michaelis, Mandy Wießner, Kristin Zoeger, and Julia Schulze, and the research team at the SRH Klinik Suhl, including Mohamed Ahmed El Sebai, Cristian-Marian Andrei, Anastasia Mihali, Mara-Viviana Crasnic, Nicole Gerlach, Gabriela Günther, Nadine Marr, and Stefanie Resiger for their support with the study. Medical writing support was provided by Qi Yan (Pfizer Inc.).


## References

1. Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, Kniss K, Burns E, Rowe T, Foust A, Jasso G, Merced-Morales A, Davis CT, Jang Y, Jones J, Daly P, Gubareva L, Barnes J, Kondor R, Sessions W, Smith C, Wentworth DE, Garg S, Havers FP, Fry AM, Hall AJ, Brammer L, Silk BJ. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021. *MMWR Morb Mortal Wkly Rep* 2021; 70(29): 1013-1019.
2. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, van der Linden MPG, Amin-Chowdhury Z, Bennett DE, Borrow R, Brandileone MC, Broughton K, Campbell R, Cao B, Casanova C, Choi EH, Chu YW, Clark SA, Claus H, Coelho J, Corcoran M, Cottrell S, Cunney RJ, Dalby T, Davies H, de Gouveia L, Deghmane AE, Demczuk W, Desmet S, Drew RJ, du Plessis M, Erlendsdottir H, Fry NK, Fuursted K, Gray SJ, Henriques-Normark B, Hale T, Hilty M, Hoffmann S, Humphreys H, Ip M, Jacobsson S, Johnston J, Kozakova J, Kristinsson KG, Krizova P, Kuch A, Ladhani SN, Lam TT, Lebedova V, Lindholm L, Litt DJ, Martin I, Martiny D, Mattheus W, McElligott M, Meehan M, Meiring S, Molling P, Morfeldt E, Morgan J, Mulhall RM, Munoz-Almagro C, Murdoch DR, Murphy J, Musilek M, Mzabi A, Perez-Arguello A, Perrin M, Perry M, Redin A, Roberts R, Roberts M, Rokney A, Ron M, Scott KJ, Sheppard CL, Siira L, Skoczynska A, Sloan M, Slotved HC, Smith AJ, Song JY, Taha MK, Toropainen M, Tsang D, Vainio A, van Sorge NM, Varon E, Vlach J, Vogel U, Vohnova S, von Gottberg A, Zanella RC, Zhou F. Changes in the incidence of invasive disease due to *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health* 2021; 3(6): e360-e370.
3. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, Weinberger DM, Dagan R. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. *Clin Infect Dis* 2022; 75(1): e1154-e1164.
4. Bertran M, Amin-Chowdhury Z, Sheppard CL, Eletu S, Zamarreño DV, Ramsay ME, Litt D, Fry NK, Ladhani SN. Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England. *Emerg Infect Dis* 2022; 28(8): 1669-1672.
5. Our World in Data. Oxford Coronavirus Government Response Tracker (OxCGRT) [cited 27. Oct 2022]; Available from: <https://ourworldindata.org/covid-stringency-index>
6. Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, Song E, Elfassy A, McNeil L, Menton R, French R, Callahan J, Webber C, Gruber WC, Bonten MJ, Jansen KU. Validation of an immunodiagnostic assay for detection of 13 *Streptococcus pneumoniae* serotype-specific polysaccharides in human urine. *Clin Vaccine Immunol* 2012; 19(8): 1131-1141.
7. Kalina WV, Souza V, Wu K, Giardina P, McKeen A, Jiang Q, Tan C, French R, Ren Y, Belanger K, McElhiney S, Unnithan M, Cheng H, Mininni T, Giordano-Schmidt D, Gessner BD, Jansen KU, Pride MW. Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional *Streptococcus pneumoniae* Serotype-specific Polysaccharides in Human Urine. *Clin Infect Dis* 2020; 71(9): e430-e438.
8. Institute for Infectious Diseases and Infection Control University Hospital Jena G. Monthly SARS-CoV-2 lineages (Thuringia). [cited 27. Oct. 2022]; Available from: <https://charts.mongodb.com/charts-routine-sequencing-sars-c-amykg/public/dashboards/e9453286-1dce-4202-9423-a8459e3962f8>
9. Bahrs C, Kesselmeier M, Kolditz M, Ewig S, Rohde G, Barten-Neiner G, Rupp J, Witzenzath M, Welte T, Pletz MW, Group CS. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. *Eur Respir J* 2022; 59(2).

10. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect* 2020.
11. Amin-Chowdhury Z, Aiano F, Mensah A, Sheppard C, Litt D, Fry NK, Andrews N, Ramsay ME, Ladhani SN. Impact of the COVID-19 Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection with SARS-CoV-2: prospective national cohort study, England. *Clin Infect Dis* 2020.
12. Bartley PS, Deshpande A, Yu PC, Klompas M, Haessler SD, Imrey PB, Zilberberg MD, Rothberg MB. Bacterial coinfection in influenza pneumonia: Rates, pathogens, and outcomes. *Infection control and hospital epidemiology* 2022; 43(2): 212-217.
13. Hyams C, Begier E, Garcia Gonzalez M, Southern J, Campling J, Gray S, Oliver J, Gessner BD, Finn A. Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology. *BMJ Open* 2022; 12(6): e057464.
14. Torres A, Menendez R, Espana PP, Fernandez-Villar JA, Marimon JM, Cilloniz C, Mendez R, Egurrola M, Botana-Rial M, Ercibengoa M, Mendez C, Cifuentes I, Gessner BD, Group CS. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. *Clin Infect Dis* 2021; 73(6): 1075-1085.
15. Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, Overcash JS, Oliva SP, File T, Wiemken TL, McLaughlin JM, Pride MW, Gray S, Alexander R, Ford KD, Jiang Q, Jodar L. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. *Vaccine* 2019; 37(25): 3352-3361.
16. Australian Government Department of Health and Aged Care. Australian Influenza Surveillance Report - No. 14, 2022, reporting fortnight: 26 September to 09 October 2022. 2022 [cited 27. Oct 2022]; Available from: [https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-ozflu-flucurr.htm/\\$File/flu-14-2022.pdf](https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-ozflu-flucurr.htm/$File/flu-14-2022.pdf)
17. The Academy of Medical Sciences. COVID-19: Preparing for the future. Looking ahead to winter 2021/22 and beyond. 2021 [cited August 10, 2021]; Available from: <https://acmedsci.ac.uk/filedownload/4747802>



## Figures



**Figure 1.** Pathogen detection among adults with community-acquired pneumonia requiring hospitalization in Thuringia, Germany in 2021. For all patients enrolled in the study, a nasopharyngeal swab and urine was collected and multiplex PCR for 10 respiratory viruses and urinary antigen tests for the C-wall polysaccharide (BinaxNow *S. pneumoniae*) and serotype antigens (urinary antigen detection assay) were performed. Results from the per-protocol and standard of care testing are shown. **A** Eligibility, enrollment, and analysis of patients with community-acquired pneumonia. **B** - Total number of enrolled adults with radiologically-confirmed, hospitalized CAP, and proportion of patients with detection of SARS-CoV-2 and *S. pneumoniae* between January 4, 2021, and December 31, 2021, by month. **C** - Proportion of CAP due to SARS-CoV-2, *S. pneumoniae* or other respiratory viruses, by age group and study period. **D** - Proportion pathogens detected, according to age group and study period. n indicates the total number of pathogen detections. Abbreviations: SARS-CoV-2 - severe acute respiratory syndrome coronavirus 2, *S. pneumoniae* – *Streptococcus pneumoniae*, HRV - human rhinovirus, PIV - parainfluenza virus 1 - 4, HMPV - human metapneumovirus, HCoV - human coronavirus (229E, OC43, NL63), RSV - respiratory syncytial virus A and B, AdV - adenovirus, HBoV - human bocavirus, CMV - cytomegalovirus.